Search filters

List of works by Margaret Macro

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

scientific article published on 19 August 2019

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

scientific article published on 11 April 2014

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

scientific article published on 19 July 2010

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

scientific article

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

scientific article published on 03 June 2019

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

scientific article

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial

scientific article published on 19 June 2019

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

scientific article published on 01 May 2019

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

scientific article published on 15 May 2019

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

scientific article published on 19 December 2019

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

scientific article published on 22 February 2020

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria

scientific article

Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study

scientific article published on 01 August 2018

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

scientific article published on April 2017

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

scientific article published on 30 April 2012

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

scientific article published on 01 October 2018

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

scientific article published on 9 January 2015

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

scientific article

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

scientific article published on 03 October 2018

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009

scientific article published on 07 July 2017

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

scientific article

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

scientific article published on 12 January 2018

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

scientific article published on 11 October 2016

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial

scientific article published on 20 June 2016

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

scientific article